Covid-19 roundup: Mod­er­na re­claims vac­cine mar­ket­ing rights in Japan; New IP waiv­er draft

Mod­er­na and Take­da ap­pear to be chang­ing their arrange­ment around the Spike­vax vac­cine dis­tri­b­u­tion in Japan.

The two phar­ma com­pa­nies will trans­fer the mar­ket­ing au­tho­riza­tion of Spike­vax from Take­da to Mod­er­na in Japan as of Au­gust 1, 2022, they said in a press re­lease Tues­day morn­ing.

Ac­cord­ing to Mod­er­na, the com­pa­ny will as­sume re­spon­si­bil­i­ty for all Spike­vax ac­tiv­i­ties, in­clud­ing im­port, lo­cal reg­u­la­to­ry, de­vel­op­ment, qual­i­ty as­sur­ance and com­mer­cial­iza­tion. Take­da’s role will con­tin­ue to pro­vide dis­tri­b­u­tion sup­port un­der Japan’s cur­rent na­tion­al vac­ci­na­tion cam­paign for Mod­er­na Covid-19 vac­cines for a tran­si­tion­al pe­ri­od. Both com­pa­nies will be re­spon­si­ble for en­sur­ing the prop­er im­ple­men­ta­tion of op­er­a­tions as­so­ci­at­ed with this trans­fer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER